Lantheus (NASDAQ:LNTH) Rating Lowered to Buy at Wall Street Zen

Lantheus (NASDAQ:LNTH) was downgraded by research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Sunday.

A number of other equities analysts also recently commented on the stock. Mizuho lifted their price objective on shares of Lantheus from $72.00 to $85.00 and gave the stock an “outperform” rating in a report on Friday, February 27th. JonesTrading cut shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. Truist Financial lifted their target price on Lantheus from $82.00 to $89.00 and gave the company a “buy” rating in a research note on Friday, February 27th. William Blair raised Lantheus from a “market perform” rating to an “outperform” rating in a report on Thursday, February 26th. Finally, Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Seven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $82.17.

Lantheus Stock Down 1.2%

Shares of Lantheus stock opened at $78.50 on Friday. The business has a 50-day moving average price of $70.72 and a 200 day moving average price of $61.98. Lantheus has a fifty-two week low of $47.25 and a fifty-two week high of $108.91. The firm has a market cap of $5.11 billion, a P/E ratio of 23.29 and a beta of -0.11. The company has a quick ratio of 2.51, a current ratio of 2.70 and a debt-to-equity ratio of 0.52.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.50. Lantheus had a return on equity of 30.77% and a net margin of 15.15%.The company had revenue of $406.79 million for the quarter, compared to the consensus estimate of $367.03 million. During the same quarter last year, the business posted $1.59 EPS. Lantheus’s quarterly revenue was up 4.0% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, sell-side analysts forecast that Lantheus will post 6.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lantheus

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Villanova Investment Management Co LLC bought a new position in Lantheus in the 4th quarter valued at about $1,511,000. Alberta Investment Management Corp acquired a new stake in shares of Lantheus in the 4th quarter worth approximately $1,617,000. Vident Advisory LLC lifted its stake in shares of Lantheus by 0.5% in the 4th quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock worth $2,979,000 after acquiring an additional 230 shares during the period. Mackenzie Financial Corp boosted its holdings in shares of Lantheus by 31.1% in the fourth quarter. Mackenzie Financial Corp now owns 657,674 shares of the medical equipment provider’s stock valued at $44,082,000 after acquiring an additional 156,081 shares in the last quarter. Finally, XTX Topco Ltd boosted its holdings in shares of Lantheus by 64.8% in the fourth quarter. XTX Topco Ltd now owns 18,440 shares of the medical equipment provider’s stock valued at $1,227,000 after acquiring an additional 7,252 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.